Optinose, Inc. reported a net loss of $22.416 million for the first quarter of 2025, an improvement from a net loss of $14.067 million in the same period last year. Total revenues increased to $18.510 million from $14.880 million, primarily due to higher XHANCE product sales. The company's cash and cash equivalents stood at $72.933 million as of March 31, 2025.

The company posted a 13% increase in net revenue for Q4 2024 compared to the prior year and recorded its first quarter with positive income from operations. However, it still reported a net loss, though significantly reduced from the previous year.

Optinose reported a 3% increase in XHANCE net revenue for Q3 2024, reaching $20.4 million. The company noted a positive inflection in new prescriptions starting in September. Financial guidance was updated, with full-year XHANCE net revenue expected to be between $75.0 and $79.0 million and operating expenses between $90.0 and $93.0 million.

Optinose reported Q2 2024 net revenue of $20.5 million, a 5% increase year-over-year. XHANCE was added to Express Scripts' national formularies. The company narrowed its full-year 2024 XHANCE net revenue guidance to $85.0 to $90.0 million and increased expected average net revenue per prescription guidance to at least $250.

Optinose reported a 26% increase in XHANCE net revenue, reaching $14.9 million for Q1 2024, compared to $11.8 million in Q1 2023. The company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million and anticipates positive income from operations (GAAP) for full year 2025.

Optinose reported Q4 2023 XHANCE net revenue of $19.9 million and a net loss of $10.0 million, or $0.09 per share. The company is preparing for the potential launch of XHANCE for chronic sinusitis, pending FDA approval.

Optinose reported Q3 2023 financial results, featuring XHANCE net revenue of $19.8 million. The company has increased its full-year 2023 XHANCE net revenue guidance and significantly improved operating efficiency with a 33% reduction in SG&A and R&D expenses year-to-date.

Optinose reported Q2 2023 financial results, featuring $19.5 million in net revenue from XHANCE sales. The company has increased its full-year revenue guidance for XHANCE and is progressing towards potential FDA approval for chronic rhinosinusitis treatment.

Optinose reported Q1 2023 net revenue of $11.8 million from XHANCE sales, a 20% decrease compared to Q1 2022. The company is preparing for a potential launch of XHANCE for chronic rhinosinusitis treatment, with the FDA accepting the sNDA for review and assigning a target goal date of December 16, 2023. They expect XHANCE net revenues for the full year 2023 to be between $62.0 to $68.0 million.

Optinose reported Q4 2022 net revenue of $20.9 million, a decrease of 7% compared to the same period in 2021. The company's net loss for the quarter was $15.1 million, or $0.17 per share. The company had cash and cash equivalents of $94.2 million as of December 31, 2022.

Optinose reported Q3 2022 XHANCE net revenue of $20.1 million. The company anticipates submitting an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023. They expect full year 2022 XHANCE net revenue to be between $74 to $78 million and full year 2022 operating expenses to be between $127 to $131 million.

Optinose reported a 12% increase in XHANCE net revenue for Q2 2022 compared to Q2 2021 and announced positive topline results from the ReOpen2 clinical trial, supporting a potential new indication for XHANCE as a treatment for chronic sinusitis. The company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis by the end of 2022.

Optinose reported first quarter 2022 financial results, with XHANCE net revenue increasing by 35% to $14.8 million compared to the first quarter of 2021. The company's net loss for the quarter was $25.3 million, or $0.31 per share.

Optinose reported XHANCE net revenue of $22.5 million for the fourth quarter of 2021. The company's net loss for the quarter was $15.6 million, or $0.23 per share. They ended the year with $110.5 million in cash and cash equivalents.

Optinose reported a 41% increase in XHANCE net revenue to $21.8 million for Q3 2021 compared to Q3 2020. The company completed enrollment in its second pivotal chronic sinusitis clinical trial and expects top-line results from the first trial in Q1 2022.

Optinose reported a strong second quarter in 2021, with XHANCE net revenue increasing by 79% compared to the second quarter of 2020. The company is focused on achieving at least $80 million in XHANCE net revenue for the full year and completing enrollment in the second chronic sinusitis pivotal clinical trial.

Optinose reported a total revenue of $12.0 million for Q1 2021, with XHANCE net revenue increasing by 55% compared to Q1 2020. The company's net loss for the quarter was $26.1 million, or $0.49 per share.

Optinose reported a net revenue of $15.6 million for XHANCE in Q4 2020, with a total revenue of $16.4 million. The company's net loss for the quarter was $23.9 million, or $0.46 per share. They ended the year with $144.2 million in cash and cash equivalents.

Optinose reported positive third-quarter results, highlighted by XHANCE net revenues of $15.4 million and a 61% increase in XHANCE prescriptions compared to the same quarter last year. The company also saw a 23% increase in new prescriptions compared to the second quarter of 2020.

Optinose reported Q2 2020 financial results, with XHANCE net revenue reaching $10.3 million. XHANCE prescriptions increased by 84% compared to Q2 2019. The company also highlighted a co-promotion agreement with kaléo and the initiation of development for a new product candidate, OPN-019.

Optinose reported a net product revenue of $7.1 million for the first quarter of 2020. The company has adapted to the COVID-19 environment by virtualizing commercial activities and reducing operating expenses. XHANCE prescriptions increased by 149% compared to the first quarter of 2019.

Optinose reported Q4 2019 XHANCE net revenue of $11.1 million, with a 26% increase in XHANCE prescriptions compared to the previous quarter. The company's cash and cash equivalents were $147.1 million as of December 31, 2019.